Abstract: The invention is related to a sample holder for measurements of optically detected magnetic resonance, including a bottom plate, a top plate and a middle plate, wherein all the plates are made of a dielectric material. The top plate is provided with at least one top opening, enabling continuous optical access to the studied sample during measurements. The sample is placed in the central opening provided in the middle plate. The non-magnetic conductive strips provided on the surfaces of the bottom plate, the middle plate and the top plate ensure formation of an electrical circuit, which allows coupling of the studied sample with the generated microwave radiation to be achieved once the microwave sources is switched on. The invention also includes a sample holder for measurements of optically detected magnetic resonance, enabling formation of at least one loop of the electrical circuit.

Abstract: The present invention is related to use of marimastat or a pharmaceutically acceptable salt, solvate or polymorph thereof in preventing or treating epileptogenesis in a subject that suffered a brain insult. Said brain insult is a stroke, traumatic brain injury, or a result of status epilepticus, evoked by structural or metabolic reasons. Marimastat or a pharmaceutically acceptable salt thereof is administered preferably within the first 24 hours after induction of epileptogenesis.

Abstract: The invention relates to a method for the preparation of cyclic compounds in the metathesis of olefins from acyclic dienes comprising terminal and/or non-terminal C?C double bonds; the invention also relates to the use of homogeneous ruthenium complexes and homogeneous ruthenium complexes deposited on a solid support as catalysts and/or pre-catalysts for the preparation of cyclic olefins in olefin metathesis reactions.

Abstract: Exemplary arrangements relate to receivers for receiving information using very weak light pulses. The exemplary arrangements include an input optical signal having a sequence of light pulses, optical elements, and a detector. The optical elements include at least one polarisation modulator, at least one polarisation splitting cube, an element with a different optical path length for different polarisations, and at least one polarization rotating plate. Part of the optical signal follows a shorter optical path length, and part of it follows a longer optical path length. The element with different optical path lengths is placed between two polarisation beam splitter cubes. The beam splitter cubes split and then merge the sequence of pulses reducing the sequence by half and forming an amplified signal readable by the detector. Exemplary arrangements also relate to a method for transmitting information using the exemplary arrangement.

Abstract: The present invention relates to nucleotides, analogs of mRNA 5?-end (cap) containing sulfur atom at the position 5? of 7-methylguanosine nucleoside. The disclosed compounds are recognized (bound and non-hydrolyzed) by DcpS enzyme (Decapping Scavenger), and thus may find therapeutic use as inhibitors thereof. DcpS is cap-specific enzyme with pyrophosphatase activity, which was identified as a therapeutic target in the treatment of spinal muscular atrophy (SMA). Some of the compounds disclosed have additional modifications in the phosphate chain, which modulate their affinity for DcpS enzyme.

Abstract: The invention pertains to novel hybrid peptidomimetics, pharmaceutical composition comprising thereof and use thereof in the treatment of neuropathic pain. The hybrid peptidomimetics according to the invention are comprised of two components: an opioid receptor agonist (OP) and a MC4 receptor antagonist, connected by a linker. The compounds of such a structure will allow to activate opioid receptors with simultaneous blocking of melanocortin type 4 receptors (MC4), which results in enhancing efficiency of the opioid therapy in neuropathic pain.

Abstract: The present invention relates to novel cyclic peptidomimetics, pharmaceutical compositions containing them and their use in the treatment of diseases associated with angiogenesis especially tumors and chronic inflammation in psoriasis, diabetes, degenerative diseases of the eye (ARMD), nephropathy and neuropathy.

Abstract: The object of the invention is a compound of formula (I), or a stereoisomer or salt thereof, wherein R1 and R2 are selected from the group consisting of N, N+—CH3, N+—C2H5, N+—C3H8, N+—C4H5, N+—CH2C6H5 wherein at least one of R1, R2 is not N. n and m are independently chosen from the group consisting of 0, 1 and 2; X is selected from the group consisting of O, NH, S, CH2 k is 1 or 2 Y is either void or selected from the group of —CH2—, —CH2CH2—, —CH2O—, —CH2S—, —CH2NH—, —CH2CH2O—, —CH2CH2NH—, —CH2CH2S— R3, R4, R5, R6 are selected from the group consisting of H, OH, OCH3, or OCH2CH3; wherein R3 and R4 may be the same or different; R5 and R6 may be the same or different; if either of R3, R4 is different than OH than R5 and R6 are both OH; if either of R5, R6 is different than OH than R3 and R4 are both OH.

Abstract: The invention relates to a method for the preparation of cyclic compounds in the metathesis of olefins from acyclic dienes comprising terminal and/or non-terminal C?C double bonds; the invention also relates to the use of homogeneous ruthenium complexes and homogeneous ruthenium complexes deposited on a solid support as catalysts and/or pre-catalysts for the preparation of cyclic olefins in olefin metathesis reactions.

Abstract: A method for synthesizing carbon nanocages, including N-doped carbon nanocages, includes a first step of forming a solution including a metal salt and an organic carbon source; a second step of drying the solution to obtain a precursor powder; and a third step of annealing the precursor powder to obtain a nanocage including a metal nanoparticle surrounded by a carbon shell. The metal nanoparticle is then removed from the carbon shell by applying an acid solution.

Abstract: We disclose novel peptidomimetics with antiangiogenic activity and their uses, particularly in the treatment of neoplasms and chronic inflammation (in particular of: rheumatoid arthritis, colitis), in eczema, diabetes, age-related macular degeneration (ARMD), nephropathy and neuropathy, in particular for use in the form of intravenous infusions or injections, or implants releasing the active ingredient.

Abstract: The present invention provides a catalyst comprising a layer of metallic palladium implant¬ed with an inert gas ions, an electrochemical system containing thereof, a palladium-inert gas alloy stable in the normal conditions, use thereof and a fuel cell containing thereof.

Abstract: The invention provides a method of preparing pure precious metal nanoparticles of controlled sizes and having (100) facets, wherein a precursor substance contained in a reagent solution is subjected to a reduction reaction using a reducing agent contained in the reagent solution to provide nanoparticles, and the reduction reaction is stopped by rapid lowering of the reaction solution temperature. In the process of the invention, the need to use surfactants or other organic particles to stabilize the (100) facets is eliminated.

Abstract: The invention refers to a chamber for measurements of electrical properties of reactive powder or liquid samples, allowing the measurement of various electrical parameters to be carried out. The present invention provides the chamber in two variants of embodiment: the multiple use chamber and the single use chamber. The construction of the chamber provides the possibility of carrying out the measurements with the sample placed directly between parallel active surfaces of the electrodes placed coaxially and sliding in a precise manner in to a thin-walled cylinder made of insulating material providing electric insulation. Elements remaining in contact with the sample are made of chemically inert materials. Additionally, a module containing a pair of the electrodes and the cylinder made of insulating material is detachable from the rest of device elements, that enables its loading and hermetic closure in a glovebox filled with inert gas.

Abstract: The invention relates to a consortium of microorganisms capable of hydrolyzing cellulose, preferably lignocellulosic biomass, which may comprise the following mixtures of bacterial strains: Bacillus sp. KP7, KP20 and Ochrobactrum sp. KP8 (the mixture deposited in PCM under the no. B/00064), Providencia sp. KP14; Bacillus sp. KP6 and KP16 (the mixture deposited in PCM under the no. B/00065), Bacillus sp. KP4, KP5, KP17 and KP22 (the mixture deposited in PCM under the no. B/00066), Providencia sp. KP10; Bacillus sp. KP1 and KP19 (the mixture deposited in PCM under the no. B/00067), Ochrobactrum sp. KP13; Bacillus sp. KP9 and KP12 (the mixture deposited in PCM under the no. B/00068), as well as a preparation for hydrolyzing cellulose which may comprise this consortium, a supplement preparation, a combination preparation, and use and method of using the same.

Abstract: The object of the invention is the plasmid pSheB, particularly a plasmid which may comprise a fragment of pSheB including the arr module and functional derivatives thereof, and strains containing such a plasmid, preferably the Shewanella sp. strain, deposited as KKP 2045p, which are capable of removing arsenic by dissolution of minerals and reduction of arsenates to arsenites. The object of the invention is also the method and the use of such bacterial strains or compositions which may comprise them, for the selective removal of arsenic from mineral resources, raw materials industry waste or soil.

Abstract: The present invention relates to modification of RNA with 5?-cap analogs of Formula (1): wherein R1-R6 and n are as described herein, in order to improve the stability and increase the expression of said RNA, in particular in immature antigen presenting cells. The present invention provides a vaccine composition comprising said stabilized RNA, immature antigen presenting cells comprising said stabilized RNA, and methods for stimulating and/or activating immune effector cells and for inducing an immune response in an individual using said stabilized RNA.

Abstract: The invention provides novel strains Agrobacterium tumefaciens KKP 2039p and Paracoccus alcaliphilus KKP 2040p, the plasmid pSinA and its functional derivative, method for producing bacterial strains capable of chemolithotrophic arsenite oxidation and novel bacterial strains produced by this method. The invention also relates to the composition, comprising the novel bacterial strain or the plasmid pSinA and the use of these novel strains, as well as the method of bioaugmentation of an arsenic contaminated environment, particularly the method for the removal of arsenic from waters.

Abstract: The invention relates to a method of synthesis of substantially pure nanoparticles in a continuous-flow system, in which a precursor substance solution undergoes reduction reaction using a reducing agent solution and nanoparticles are produced, wherein the reduction reaction is terminated by adding an agent neutralizing the reducing agent and a stable nanoparticle colloid is produced. In the method of the invention a need for using surfactants or other organic molecules for nanoparticle stabilization has been eliminated.

Abstract: The object of the present invention is a composition of bacterial strains which may comprise Stenotrophomonas sp. strain 2L, Stenotrophomonas sp. strain 5L, Stenotrophomonas sp. strain 6L, Stenotrophomonas sp. strain 3N, Achromobacter sp. strain 4P, Arthrobacter sp. strain 1N, Brevundimonas sp. strain 2N, Brevundimonas sp. strain 5N, Brevundimonas sp. strain 6N, Pseudomonas sp. strain 3G, and Pseudomonas sp. strain 4, deposited under the number KKP 2041p (IAFB Collection of Industrial Microorganisms—Institute of Agricultural and Food Biotechnology in Warsaw), a bioremediation vaccine (bioremediation mixture) which may comprise the composition of these strains, the use of the vaccine in the removal of contaminants from the soil, and the method for the treatment of contaminated soil.